Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria

Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria

<p><strong>Background</strong> Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-aminoquinoline th...

Descripció completa

Dades bibliogràfiques
Autors principals:	Lacerda, MVG, Llanos-Cuentas, A, Krudsood, S, Lon, C, Saunders, DL, Mohammed, R, Yilma, D, Batista Pereira, D, Espino, FEJ, Mia, RZ, Chuquiyauri, R, Val, F, Casapía, M, Monteiro, WM, Brito, MAM, Costa, MRF, Buathong, N, Noedl, H, Diro, E, Getie, S, Wubie, KM, Abdissa, A, Zeynudin, A, Abebe, C, Tada, MS, Brand, F, Beck, H-P, Angus, B, Duparc, S, Kleim, J-P, Kellam, LM, Rousell, VM, Jones, SW, Hardaker, E, Mohamed, K, Clover, DD, Fletcher, K, Breton, JJ, Ugwuegbulam, CO, Green, JA, Koh, GCKW
Format:	Journal article
Idioma:	English
Publicat:	Massachusetts Medical Society 2019

Ítems similars

Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria
per: Llanos-Cuentas, A, et al.
Publicat: (2019)

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
per: St Jean, PL, et al.
Publicat: (2020)

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis
per: Watson, JA, et al.
Publicat: (2022)

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis'
per: Watson, JA, et al.
Publicat: (2024)

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.
per: Mark M Fukuda, et al.
Publicat: (2017-01-01)

Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
per: Stephan Duparc, et al.
Publicat: (2020-03-01)

Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers
per: Rueangweerayut, R, et al.
Publicat: (2017)

Tafenoquine — a radical improvement?
per: White, N
Publicat: (2019)

The antimalarial activity of tafenoquine in falciparum malaria
per: White, NJ
Publicat: (2023)

Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria
per: Raman Sharma, et al.
Publicat: (2024-05-01)

Tafenoquine for travelers' malaria: evidence, rationale and recommendations
per: Baird, J
Publicat: (2018)

Tafenoquine for the prevention of Plasmodium vivax malaria relapse
per: Watson, JA, et al.
Publicat: (2021)

Tafenoquine for children: a step towards implementation
per: Commons, RJ, et al.
Publicat: (2021)

Repurposing of the antimalarial agent tafenoquine to combat MRSA
per: Pengfei She, et al.
Publicat: (2023-12-01)

Quantification of Tafenoquine and 5,6-Orthoquinone Tafenoquine by UHPLC-MS/MS in Blood, Plasma, and Urine, and Application to a Pharmacokinetic Study
per: Geoffrey W. Birrell, et al.
Publicat: (2022-11-01)

Tafenoquine and G6PD: a primer for clinicians
per: Chu, CS, et al.
Publicat: (2019)

Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
per: Watson, J, et al.
Publicat: (2019)

Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies
per: Luisa Oliveira Santos, et al.
Publicat: (2024-08-01)

The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
per: James A Watson, et al.
Publicat: (2022-12-01)

Single loading-dose tafenoquine for malaria chemoprophylaxis during brief travel?
per: Baird, JK
Publicat: (2021)

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'
per: James A Watson, et al.
Publicat: (2024-02-01)

Determination of tafenoquine in dried blood spots and plasma using LC and fluorescence detection.
per: Römsing, S, et al.
Publicat: (2011)

Determination of tafenoquine in dried blood spots and plasma using LC and fluorescence detection
per: Romsing, S, et al.
Publicat: (2011)

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
per: Watson, J, et al.
Publicat: (2018)

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
per: James Watson, et al.
Publicat: (2018-04-01)

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency
per: Commons, RJ, et al.
Publicat: (2020)

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date
per: Ebstie YA, et al.
Publicat: (2016-07-01)

Relapses of Plasmodium vivax malaria threaten disease elimination: time to deploy tafenoquine in India?
per: Amit Sharma, et al.
Publicat: (2021-02-01)

Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo
per: Leonardo J. M. Carvalho, et al.
Publicat: (2020-07-01)

Extended blood stage sensitivity profiles of Plasmodium cynomolgi to doxycycline and tafenoquine, as a model for Plasmodium vivax
per: Christensen, Peter, et al.
Publicat: (2024)

Radical curative efficacy of tafenoquine combination regimens in <it>Plasmodium cynomolgi</it>-infected Rhesus monkeys (<it>Macaca mulatta</it>)
per: Kenworthy David, et al.
Publicat: (2011-07-01)

Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum
per: Karen Kemirembe, et al.
Publicat: (2017-08-01)

Enantiomeric resolution of primaquine, quinacrine and tafenoquine antibacterial medicines using ristocetin macrocyclic glycopeptide antibiotics CSP
per: Zeid A. ALOthman, et al.
Publicat: (2020-01-01)

Comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'
per: Raman Sharma, et al.
Publicat: (2024-02-01)

Phytochemical Screening and Antimicrobial Activity Evaluation of Selected Medicinal Plants in Ethiopia
per: Dubale S, et al.
Publicat: (2023-02-01)

A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.
per: Hale, B, et al.
Publicat: (2003)

Efficacy Evaluation of 10-Hydroxy Chondrofoline and Tafenoquine against <i>Leishmania tropica</i> (HTD<sub>7</sub>)
per: Sayyed Ibrahim Shah, et al.
Publicat: (2022-08-01)

Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate <i>Babesia microti</i> Infection in an Immunocompromised Patient
per: Prithiv J. Prasad, et al.
Publicat: (2022-09-01)

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data
per: Hounkpatin AB, et al.
Publicat: (2019-03-01)

The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg)
per: Geoffrey Dow, et al.
Publicat: (2017-05-01)